The departing director of the US Food and Drug Administration’s Center for Drug Evaluation and Research believes her staff is in “the best place possible” as it enters the new year and a new administr
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
In the top M&A, Baxter International Inc. signed a definitive agreement in which investment firm Carlyle will acquire its kidney care segment, to be named Vantive, for $3.8bn. Vantive offers product